CytomX Therapeutics Inc(CTMX) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Current Price

$8.55

RSI

42.599

Beta:

0.616105

February 24, 2021
24.9M
-17.9M

97.765 %
101.030 %
59.023 %
45.469 %

$100,362,000
$57,489,000
$59,502,000
$71,623,000
$15,043,000
$7,712,000
74.576 %
-3.502 %
-20.371 %
376.122 %
95.060 %

$-46,785,000
$-102,665,000
$-70,301,000
$-43,612,000
$-58,919,000
$-35,364,000
119.440 %
-31.524 %
-37.964 %
35.098 %
-39.979 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.